Background: We sought to comprehensively summarize available evidence for the use of VEGF-C protein to evaluate the clinicopathological and prognostic role of VEGF-C in colorectal cancer.
Methods: Electronic databases from inception to February 2016 were used to search without language restrictions for original articles. A meta-analysis was undertaken to assess the relationship between VEGF-C expression and overall survival (OS) in colorectal cancer.
Results: Twenty-seven studies were included in the final meta-analysis. We aggregated 13 trials (n = 1.428 patients) that evaluated the correlation between OS and VEGF-C overexpression. Statistics were performed for OS (HR = 1.95; 95%CI = 1.31-2.92, P = 0.007). When the studies were stratified by the pathological variables, including T stage (n = 383 patients; OR = 1.79; 95%CI = 1.14-2.81), lymph node metastasis (n = 3212 patients; OR = 4.21; 95%CI = 3.49-5.08), M stage (n = 1106 patients; OR = 4.46; 95%CI = 2.96-6.70), vascular invasion(n = 1471 patients; OR = 2.18; 95%CI = 1.65-2.88), lymph invasion (n = 831 patients; OR = 3.95; 95%CI = 2.80-5.56), histo-differentiation (n = 1695 patients; OR = 1.34; 95%CI = 1.00-1.79) and Duke's stage(n = 778 patients; OR = 4.90; 95%CI = 3.55-6.75), TNM stage (n = 808 patients; OR = 1.73; 95%CI = 1.18-2.54) provided critical and comprehensive prognostic information.
Conclusion: Our results demonstrated that VEGF-C overexpression was associated with OS in colorectal cancer. (C) 2016 Elsevier B.V. All rights reserved.
[1]Shanghai TCM Univ, Shanghai Municipal Hosp Tradit Chinese Med, Dept Oncol, 274 Zhijiang Rd, Shanghai 200071, Peoples R China.
(8.0+极速模式)